


REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)



In re Application of

Application Number

081846,017

Filed

4/25/97

Art Unit

Examiner

Paper No. 34

Assistant Commissioner for Patents
Washington, DC 20231

1. ☒ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☐ (A) referred to in:

United States Patent Application Publication No. 6475789, page _____, line _____,

United States Patent Number _____, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Arieb Tesfay
Signature
Arieb Tesfay
Typed or printed name

6/9/03
Date

FOR PTO USE ONLY

Approved by: SA

(initials)

Unit: _____



US006475789B1

(12) **United States Patent**
Cech et al.

(10) Patent No.: **US 6,475,789 B1**
(45) Date of Patent: ***Nov. 5, 2002**

(54) **HUMAN TELOMERASE CATALYTIC
SUBUNIT: DIAGNOSTIC AND
THERAPEUTIC METHODS**

6,261,836 B1 7/2001 Cech et al.

FOREIGN PATENT DOCUMENTS

- (75) Inventors: **Thomas R. Cech**, Boulder, CO (US);
Joachim Lingner, Epalinges (CH);
Toru Nakamura, Boulder, CO (US);
Karen B. Chapman, Sausalito, CA
(US); **Gregg B. Morin**, Palo Alto, CA
(US); **Calvin B. Harley**, Palo Alto, CA
(US); **William H. Andrews**, Richmond,
CA (US)
- (73) Assignees: **University Technology Corporation**,
Boulder, CO (US); **Geron Corporation**,
Menlo Park, CA (US)

JP	09154575 A	6/1997
WO	WO 84/03564	9/1984
WO	WO 95/13382	5/1995
WO	WO 96/01835	1/1996
WO	WO 96/12811	5/1996
WO	WO 96/19580	6/1996
WO	WO 96/40868	12/1996
WO	WO 98/01542	1/1998
WO	WO 98/01543	1/1998
WO	WO 98/08938	2/1998
WO	WO 98/07838	3/1998
WO	WO 98/21343	5/1998
WO	WO 98/37181	8/1998
WO	WO 98/45450	10/1998

- (*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

- (21) Appl. No.: **08/912,951**
(22) Filed: **Aug. 14, 1997**

Related U.S. Application Data

- (63) Continuation-in-part of application No. 08/845,050, filed on
May 9, 1997, now Pat. No. 5,743,518, which is a continu-
ation-in-part of application No. 08/851,843, filed on May 6,
1997, now Pat. No. 6,093,809, which is a continuation-in-
part of application No. 08/846,017, filed on Apr. 25, 1997,
now abandoned, which is a continuation-in-part of applica-
tion No. 08/844,419, filed on Apr. 18, 1997, now abandoned,
which is a continuation-in-part of application No. 08/724,
643, filed on Oct. 1, 1996, now abandoned.
- (51) Int. Cl.⁷ **C12N 5/08; C12N 15/12;**
C07H 21/04; A61K 38/43
- (52) U.S. Cl. **435/366; 435/320.1; 435/69.1;**
536/23.2; 424/94.1
- (58) Field of Search **435/366, 320,**
435/69.1; 536/23.2; 429/94.1

- (56) **References Cited**

U.S. PATENT DOCUMENTS

3,817,837 A	6/1974	Tanenholtz et al.	195/103.5
3,850,752 A	11/1974	Schuurs et al.	195/103.5
3,939,350 A	2/1976	Kronick et al.	250/365
3,996,345 A	12/1976	Ullman et al.	424/12
4,275,149 A	6/1981	Litman et al.	435/7
4,277,437 A	7/1981	Maggio	422/61
4,366,241 A	12/1982	Tom et al.	435/7
4,683,195 A	7/1987	Mullis et al.	435/6
4,683,202 A	7/1987	Mullis	435/91
4,816,567 A	3/1989	Cabilly et al.	530/387
4,965,188 A	10/1990	Mullis et al.	435/6
5,489,508 A	2/1996	West et al.	435/6
5,583,016 A	12/1996	Villeponteau et al.	435/91.3
5,747,317 A	5/1998	Cao	
5,770,422 A	6/1998	Collins	
6,258,535 B1	7/2001	Villeponteau et al.	
6,261,556 B1	7/2001	Weinrich et al.	

OTHER PUBLICATIONS

Johnson et al., *Mol. Cell. Biol.* 1991, vol. 11, pp. 1-11.*
Counter et al., *Proc. Nat. Acad. Sci.* 1994, vol. 91, pp.
2900-2904.*
Zakian, "Telomeres: Beginning to Understand the End,"
Science 270:1601 [1995].
Blackburn and Gall, "A tandemly repeated sequence at the
termini of the extrachromosomal ribosomal RNA genes in
Tetrahymena," *J. Mol. Biol.*, 120:33 [1978].
Oka et al., "Inverted terminal repeat sequence in the macro-
nuclear DNA of *Stylonychia pustulata*," *Gene* 10:301
[1980].
Klobutcher et al., "All gene-sized DNA molecules in four
species of hypotrichs have the same terminal sequence and
an unusual 3' terminus," *Proc. Natl. Acad. Sci.*, 78:3015
[1981].
Lingner et al., "Telomerase RNAs of different ciliates have a
common secondary structure and a permuted template,"
Genes Develop., 8:1984 [1994].
Biessmann et al., "Addition of Telomere-Associated HeT
DNA Sequences "Heals" Broken Chromosome Ends in
Drosophila," *Cell* 61:663 [1990].
Sheen and Levis, "Transposition of the LINE-like ret-
rotransposon TART to *Drosophila* chromosome termini,"
Proc. Natl. Acad. Sci., 91:12510 [1994].
Kipling and Cooke, "Hypervariable ultra-long telomeres in
mice," *Nature* 347:400 [1990].

(List continued on next page.)

Primary Examiner—Yvonne Eyler

Assistant Examiner—Janet L. Andres

(74) *Attorney, Agent, or Firm*—J. Michael Schiff; David J.
Earp; Scott L. Ausenhus

(57) **ABSTRACT**

The invention provides compositions and methods related to
human telomerase reverse transcriptase (hTERT), the cata-
lytic protein subunit of human telomerase. The polynucle-
otides and polypeptides of the invention are useful for
diagnosis, prognosis, and treatment of human diseases, for
changing the proliferative capacity of cells and organisms,
and for identification and screening of compounds and
treatments useful for treatment of diseases such as cancers.

8 Claims, 34 Drawing Sheets